Not provided
Not provided
Not provided
Not provided
Recruitment is suspended due to funding issues
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Association pour la Recherche sur la Sclérose Latérale Amyotrophique et autres Maladies du Motoneurone | UNKNOWN |
| Groupe Hospitalier Pitie-Salpetriere | OTHER |
| Institut de Myologie, France | OTHER |
Not provided
Not provided
Not provided
Using a MRI gait motor imagery paradigm in ALS patients in order to study how ALS affects the function of the central neural networks involved in gait function, we showed a reorganization of the motor networks that represents a compensatory response to the dysfunction of the networks involved in gait function. Our main hypothesis is that by providing coherent proprioceptive input to the sensorimotor integration areas, gait training with an exoskeleton may boost compensatory network reorganization and help to maintain function. We hypothesize that this can be achieved through a locomotion training strategy that reproduces normal gait motor patterns and appropriate sensory feedback. Gait training with an exoskeleton can meet these needs. The Atalante exoskeleton offers unique potential thanks to its cutting-edge technological features, hands-free functions and availability in numerous centers across Europe. Evaluation of its safety and efficacy in ALS is of the utmost interest in order to generalize this new approach in ALS.
Current research is mainly focused on evaluating the effect of robotic rehabilitation on locomotion in ALS. In order to understand this approach, it is important to validate its safety and to determine patient's experience with this new rehabilitation concept in ALS. In this study, we aim to evaluate the safety, the participant experience and effectiveness of the training program with the Atalante exoskeleton as a gait training tool for ALS patients, compared with usual care, on walking ability, functional capacity and other symptoms associated with motor disability. The Atalante exoskeleton is the only self-balancing exoskeleton that enables assisted walking without walking aid, reproducing a natural walking pattern and multidirectional movement. EXALS is an interventional, monocentric, prospective, open trial. With a limited number of studies on gait rehabilitation exoskeletons in ALS, this study represents a significant scientific contribution, being the first to explore the benefits of a self-balancing exoskeleton with a rigorous design. In addition to robust outcome measures, this study places importance on participants' perception, motivation, and involvement in decision-making, adding depth and strength to the research.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patient | Other | Single-group study following an ABA design: Phase A1 (usual care for 6 weeks) Phase B (usual care + gait training using exoskeleton for 6 weeks) Phase A2 (usual care for 6 weeks) All participants undergo the same sequence of conditions according to the protocol. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Atalante exoskeleton | Device | The gait training program using Atalante exoskeleton consisted of 3 sessions per week for 6 weeks. Each session includes the patient's installation and de-installation (10 min), walking training (30 min), and physical activities at the end of the session where the patient is in an upright position in the exoskeleton (e.g. badminton, boxing, or basketball) (5-10 min). For each participant, the assistance of the exoskeleton can be specifically adjusted and can be set symmetrically or asymmetrically bases on his capabilities. |
| Measure | Description | Time Frame |
|---|---|---|
| Safety of Atalante exoskeleton | Monitoring adverse events | During the three consecutive phases of the study (A1, B, and A2), from baseline (Week 0) through Week 18, with assessments at Weeks 0, 3, 6, 9, 12, 15, and 18 and during all training sessions in phase B |
| Measure | Description | Time Frame |
|---|---|---|
| Functional capacity | ALSFRS-R | During the three consecutive phases of the study (A1, B, and A2), from baseline (Week 0) through Week 18, with assessments at Weeks 0, 3, 6, 9, 12, 15, and 18 (7 assessments in total) |
| Pulmonary function |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ghida TRAD, PhD | Sorbonne Université, Inserm, CNRS, Laboratoire d'Imagerie Biomédicale (LIB), 75006-Paris (France), Neuromuscular Physiology and Evaluation Lab, Neuromuscular Investigation Center, Institute of Myology, 75013-Paris (France) | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Station Debout | Paris | 75001 | France | |||
| Hôpital Pitié-Salpêtrière |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26152368 | Result | Labra J, Menon P, Byth K, Morrison S, Vucic S. Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry. 2016 Jun;87(6):628-32. doi: 10.1136/jnnp-2015-310998. Epub 2015 Jul 7. | |
| 16434671 | Result | Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, Shinoda K, Sugino M, Hanafusa T. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006 Jan 24;66(2):265-7. doi: 10.1212/01.wnl.0000194316.91908.8a. |
Not provided
Not provided
Individual participant data that underlie the results reported in this article, after de-identification, may be made available upon reasonable request from the corresponding author. Data sharing will be subject to institutional and ethical approvals.
Following publication of the study results
Researchers with a methodologically sound proposal and appropriate ethical approval may request access to the de-identified data and supporting documents from the corresponding author
Not provided
Not provided
| ID | Term |
|---|---|
| D000690 | Amyotrophic Lateral Sclerosis |
| ID | Term |
|---|---|
| D013118 | Spinal Cord Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D016472 | Motor Neuron Disease |
Not provided
Not provided
| Station Debout | UNKNOWN |
| Laboratory of Biomedical Imaging | UNKNOWN |
The study will be conducted in 3 phases, each lasting 6 weeks, following the ABA procedure. Phase B represents the intervention phase, during which patients will practice their gait training at a rhythm of 3 sessions/week, as an add-on to usual care. In the two phases A, patients receive usual care with no additional treatment
Not provided
Not provided
Not provided
Not provided
|
Forced vital capacity
| During the three consecutive phases of the study (A1, B, and A2), from baseline (Week 0) through Week 18, with assessments at Weeks 0, 3, 6, 9, 12, 15, and 18 (7 assessments in total) |
| Gait ability | The 6-minute walk test, the 10-meter walk test and the Timed Up and Go test | During the three consecutive phases of the study (A1, B, and A2), from baseline (Week 0) through Week 18, with assessments at Weeks 0, 3, 6, 9, 12, 15, and 18 (7 assessments in total)l |
| Static and dynamic balance | Berg Balance Scale (0 - 56) with higher scores representing better balance | During the three consecutive phases of the study (A1, B, and A2), from baseline (Week 0) through Week 18, with assessments at Weeks 0, 3, 6, 9, 12, 15, and 18 (7 assessments in total) |
| Speed of movement of the center of pressure per second | Force platform | During the three consecutive phases of the study (A1, B, and A2), from baseline (Week 0) through Week 18, with assessments at Weeks 0, 3, 6, 9, 12, 15, and 18 (7 assessments in total) |
| Lower limb muscle strength | Isometric dynamometer | During the three consecutive phases of the study (A1, B, and A2), from baseline (Week 0) through Week 18, with assessments at Weeks 0, 3, 6, 9, 12, 15, and 18 (7 assessments in total) |
| Spasticity of knee flexor and extensor muscles | Instrumental assessment with isokinetic dynamometer | During the three consecutive phases of the study (A1, B, and A2), from baseline (Week 0) through Week 18, with assessments at Weeks 0, 3, 6, 9, 12, 15, and 18 (7 assessments in total) |
| Patient quality of life | ALSAQ-40 | During the three consecutive phases (A1, B, and A2), with assessments at baseline (Week 0), Week 6, Week 12, and Week 18 (4 assessments in total) |
| General fatigue | Fatigue Severity Scale and the Modified Fatigue Impact Scale | During the three consecutive phases (A1, B, and A2), with assessments at baseline (Week 0), Weeks 3, 6, 12, and 18 (5 assessments in total). |
| Patient pain | Brief pain inventory-short form | During the three consecutive phases (A1, B, and A2), with assessments at baseline (Week 0), Week 6, Week 12, and Week 18 (4 assessments in total). |
| Anxiety and depression | Hospital anxiety and depression scale | During the three consecutive phases (A1, B, and A2), with assessments at baseline (Week 0), Week 6, Week 12, and Week 18 (4 assessments in total). |
| Intrinsic motivation | Intrinsic motivation inventory | week 12 |
| Subjective impact of gait training with Atalante exoskeleton on participants | The participant's experience with domain-oriented exoskeleton training | week 12 |
| Participants' attitudes to Atalante gait training | Net promoter score | week 12 |
| Efficacy and interactivity of the Atalante exoskeleton | A specific questionnaire was developed to assess the efficacy and interactivity of the Atalante exoskeleton | Week 12 |
| Participants' experience of gait training with Atalante exoskeleton | Semi-structured interview | week 12 |
| Paris |
| 75013 |
| France |
| Institut de myologie | Paris | 75013 | France |
| 32896088 | Result | Abidi M, de Marco G, Grami F, Termoz N, Couillandre A, Querin G, Bede P, Pradat PF. Neural Correlates of Motor Imagery of Gait in Amyotrophic Lateral Sclerosis. J Magn Reson Imaging. 2021 Jan;53(1):223-233. doi: 10.1002/jmri.27335. Epub 2020 Sep 7. |
| 42387593 | Derived | Trad G, Lenglet T, Ledoux I, Querin G, Blancho S, Marchand-Pauvert V, Hogrel JY, Pradat PF. Safety, feasibility and preliminary effects of Atalante exoskeleton-assisted gait training in amyotrophic lateral sclerosis: a prospective ABA pilot study. J Neuroeng Rehabil. 2026 Jul 1. doi: 10.1186/s12984-026-02046-y. Online ahead of print. |
| 42026110 | Derived | Trad G, Lenglet T, Ledoux I, Querin G, Blancho S, Marchand-Pauvert V, Pradat PF, Hogrel JY. Exploring the interplay between quantitative muscle strength, functional performance, and patient-reported outcomes in amyotrophic lateral sclerosis: a cross-sectional pilot study. Sci Rep. 2026 Apr 24;16(1):18813. doi: 10.1038/s41598-026-45898-z. |
| 41545051 | Derived | Trad G, Lenglet T, Ledoux I, Querin G, Blancho S, Marchand-Pauvert V, Hogrel JY, Pradat PF. Safety and efficacy of the Atalante exoskeleton in the rehabilitation of French patients with amyotrophic lateral sclerosis: a prospective, monocentric, open, uncontrolled, interventional protocol, EXALS. BMJ Open. 2026 Jan 16;16(1):e109620. doi: 10.1136/bmjopen-2025-109620. |
| D019636 | Neurodegenerative Diseases |
| D057177 | TDP-43 Proteinopathies |
| D009468 | Neuromuscular Diseases |
| D057165 | Proteostasis Deficiencies |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |